Astex is dedicated to the discovery and development of novel small molecule therapeutics with a primary focus on oncology. The Company, which is a recognised leader in the field of Fragment Based Drug Discovery, is developing a proprietary pipeline of novel therapies and has a number of other programmes partnered with major pharmaceutical companies with products in clinical development. . . In October 2013, Astex was acquired by Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan. . . For more information about Astex please visit http://www.astx.com
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.. . We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.. . We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia)
No data available
At AviadoBio, our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute. AviadoBio’s unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery.
AviadoBio’s investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc.
The company is developing AVB-101 for patients with FTD-GRN. AVB-101 is an investigational AAV gene therapy designed to slow or stop disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore progranulin levels.
AviadoBio’s investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc.
The company is developing AVB-101 for patients with FTD-GRN. AVB-101 is an investigational AAV gene therapy designed to slow or stop disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore progranulin levels.
Babraham Institute Enterprise Limited (BIE) is the wholly-owned trading arm of the Babraham Institute. The Babraham Institute undertakes innovative life-sciences research to discover the molecular mechanisms that underlie normal cellular processes and functions, with the aim of improving lifelong wellbeing and healthy ageing. It is based on the Babraham Research Campus near Cambridge, which is also home to early-stage biomedical companies.. . The Institute aims to maximise the impact of its research through knowledge exchange and commercialisation, and its scientists work with other organisations to translate that research into action for social and economic benefit. BIE supports the delivery of the commercialisation of the Babraham Institute's science. As part of this role, it manages, develops and commercialises the Babraham Institute's intellectual property portfolio. It also facilitates collaborations between the Institute and industry, and arranges access to the Institute's expertise and scientific facilities and services.
Babraham Research Campus Ltd is the company that manages and develops the Babraham Research Campus, supporting and promoting the regional and UK bioscience ecosystem. It has responsibility for the administration and commercial development of the site for the benefit of all the tenants including the Babraham Institute. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. Watch our Member Showcase video here https://bit.ly/3A1MjXZ
No data available
No data available
BBI Cambridge is the UK operating company of the Biotechnology Business Institute based in Barcelona.
No data available